Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
XFOR logo XFOR
Upturn stock ratingUpturn stock rating
XFOR logo

X4 Pharmaceuticals Inc (XFOR)

Upturn stock ratingUpturn stock rating
$3.14
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: XFOR (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

5 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $41.08

1 Year Target Price $41.08

Analysts Price Target For last 52 week
$41.08 Target price
52w Low $1.35
Current$3.14
52w High $26.82

Analysis of Past Performance

Type Stock
Historic Profit -10.07%
Avg. Invested days 28
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 35.82M USD
Price to earnings Ratio -
1Y Target Price 41.08
Price to earnings Ratio -
1Y Target Price 41.08
Volume (30-day avg) 5
Beta 0.6
52 Weeks Range 1.35 - 26.82
Updated Date 08/15/2025
52 Weeks Range 1.35 - 26.82
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -15.14

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Earnings Date

Report Date 2025-07-31
When -
Estimate -0.0883
Actual -3.47

Profitability

Profit Margin -
Operating Margin (TTM) -1329.55%

Management Effectiveness

Return on Assets (TTM) -41.92%
Return on Equity (TTM) -207.22%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 50895240
Price to Sales(TTM) 1.09
Enterprise Value 50895240
Price to Sales(TTM) 1.09
Enterprise Value to Revenue 1.55
Enterprise Value to EBITDA 1.1
Shares Outstanding 11408400
Shares Floating 8603156
Shares Outstanding 11408400
Shares Floating 8603156
Percent Insiders 1.29
Percent Institutions 25.89

ai summary icon Upturn AI SWOT

X4 Pharmaceuticals Inc

stock logo

Company Overview

overview logo History and Background

X4 Pharmaceuticals, founded in 2014, is a biopharmaceutical company focused on discovering and developing novel therapeutics to improve immune cell trafficking to treat diseases resulting from immune dysfunction. The company went public in 2017.

business area logo Core Business Areas

  • Drug Development: Focuses on the development of therapies for rare diseases by restoring normal immune cell trafficking.

leadership logo Leadership and Structure

Paula Ragan, Ph.D., is the President and CEO. The company has a typical biotech structure with R&D, clinical development, and commercial functions.

Top Products and Market Share

overview logo Key Offerings

  • Mavorixafor: Mavorixafor is X4 Pharmaceutical's lead drug candidate, an oral, once-daily CXCR4 antagonist. Mavorixafor is being studied for WHIM syndrome, a rare primary immunodeficiency disease. The market for rare immunodeficiencies is relatively untapped. Competitors depend on indication and might include companies developing gene therapies or other targeted therapies for similar conditions.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and regulatory hurdles. Companies focus on specific disease areas or therapeutic platforms.

Positioning

X4 Pharmaceuticals is positioned as a company specializing in rare diseases, targeting unmet medical needs through its CXCR4 antagonist platform.

Total Addressable Market (TAM)

The TAM for therapies addressing rare immunodeficiency diseases is estimated to be in the billions of dollars, driven by high unmet need and potential for orphan drug designation. X4 is positioned to capture a share of this TAM with mavorixafor.

Upturn SWOT Analysis

Strengths

  • Novel CXCR4 antagonist platform
  • Lead product with orphan drug potential
  • Experienced management team
  • Focus on rare diseases with unmet needs

Weaknesses

  • Reliance on single product candidate
  • High cash burn rate
  • Clinical trial risk
  • Limited commercialization experience

Opportunities

  • Expansion of mavorixafor into additional indications
  • Potential partnerships with larger pharmaceutical companies
  • Acquisition or licensing of new assets
  • Positive clinical trial results

Threats

  • Clinical trial failure
  • Regulatory delays or rejection
  • Competition from other therapies
  • Financing risk

Competitors and Market Share

competitor logo Key Competitors

  • SAN
  • BMY
  • REGN

Competitive Landscape

X4's competitive advantages are its novel CXCR4 antagonist platform and focus on rare diseases. Disadvantages include its limited financial resources and reliance on a single product candidate.

Growth Trajectory and Initiatives

Historical Growth: Growth is contingent on the successful development and commercialization of mavorixafor.

Future Projections: Future projections are based on analyst estimates, which factor in clinical trial outcomes and market penetration.

Recent Initiatives: Focus is on advancing mavorixafor through clinical trials and preparing for potential commercialization.

Summary

X4 Pharmaceuticals is a clinical-stage biopharmaceutical company with a focus on developing therapies for rare diseases. It holds promise with its lead drug candidate, mavorixafor; however, the company faces the risks inherent in drug development and a need for further funding. Successful clinical trial outcomes and regulatory approvals will be crucial for its long-term success. It's financial metrics need to be watched closely. The market is competitive with larger pharmaceuticals, and thus partnerships would be beneficial.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company SEC filings
  • Company website
  • Analyst reports
  • Industry publications

Disclaimers:

The data provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About X4 Pharmaceuticals Inc

Exchange NASDAQ
Headquaters Boston, MA, United States
IPO Launch date 2017-11-16
CEO -
Sector Healthcare
Industry Biotechnology
Full time employees 143
Full time employees 143

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company also develops mavorixafor that is in Phase 3 4WARD clinical trial to evaluate the efficacy, safety, and tolerability of oral, once-daily mavorixafor with or without stable doses of G-CSF in people with congenital, acquired primary autoimmune, or idiopathic CN who are experiencing recurrent and/or serious infections. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications; and with Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand. The company is headquartered in Boston, Massachusetts.